Further evidence that Pcdh10 acts as an oncosuppressor derives from the observations that downregulated Pcdh10 expression caused by methylation predicted poor prognosis in patients with hepatocellular carcinoma (Bing et al. 2018), breast cancer (Liu et al. 2018b; Xu et al. 2021), prostate cancer (Wang et al. 2014; Deng et al. 2016), and non-small-cell lung cancer (Harada et al. 2015). Here, PCDH10 is linked to Familial prostate cancer.